Insulet Co. (NASDAQ:PODD) Holdings Lifted by Great Lakes Advisors LLC

Great Lakes Advisors LLC increased its holdings in shares of Insulet Co. (NASDAQ:PODD) by 34.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,478 shares of the medical instruments supplier’s stock after buying an additional 893 shares during the quarter. Great Lakes Advisors LLC’s holdings in Insulet were worth $908,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. Sequoia Financial Advisors LLC boosted its position in Insulet by 2.4% during the fourth quarter. Sequoia Financial Advisors LLC now owns 2,170 shares of the medical instruments supplier’s stock valued at $566,000 after purchasing an additional 50 shares during the last quarter. Wealthfront Advisers LLC boosted its position in Insulet by 385.8% during the fourth quarter. Wealthfront Advisers LLC now owns 18,860 shares of the medical instruments supplier’s stock valued at $4,924,000 after purchasing an additional 14,978 shares during the last quarter. Citizens Financial Group Inc. RI acquired a new stake in Insulet during the fourth quarter valued at $341,000. Independent Advisor Alliance boosted its position in Insulet by 20.8% during the fourth quarter. Independent Advisor Alliance now owns 1,378 shares of the medical instruments supplier’s stock valued at $360,000 after purchasing an additional 237 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its position in Insulet by 22.1% during the fourth quarter. Daiwa Securities Group Inc. now owns 15,114 shares of the medical instruments supplier’s stock valued at $3,946,000 after purchasing an additional 2,736 shares during the last quarter.

Insider Activity at Insulet

In other news, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. This represents a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.47% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on PODD shares. Citigroup lifted their price objective on Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research report on Friday, February 21st. JPMorgan Chase & Co. boosted their price target on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research report on Thursday, December 12th. Royal Bank of Canada initiated coverage on Insulet in a research report on Thursday, March 6th. They issued an “outperform” rating and a $340.00 price target for the company. Raymond James reaffirmed an “outperform” rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. Finally, Canaccord Genuity Group boosted their price target on Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $292.06.

Insulet Trading Up 4.4 %

Shares of PODD opened at $255.44 on Friday. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $289.46. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The firm has a market capitalization of $17.94 billion, a price-to-earnings ratio of 44.12, a P/E/G ratio of 3.62 and a beta of 1.29. The stock’s 50-day moving average price is $272.54 and its 200 day moving average price is $254.96.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. As a group, research analysts predict that Insulet Co. will post 3.92 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.